cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Dyne Therapeutics Inc
6 own
5 watching
Current Price
$27.38
$0.55
(2.05%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
635.54M
52-Week High
52-Week High
30.26900
52-Week Low
52-Week Low
6.40000
Average Volume
Average Volume
0.74M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
-1.35986159
iconMarket Capitalization635.54M
icon52-Week High30.26900
icon52-Week Low6.40000
iconAverage Volume0.74M
iconDividend Yield--
iconP/E Ratio-1.35986159
What does the Dyne Therapeutics Inc do?
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..
Read More
How much money does Dyne Therapeutics Inc make?
News & Events about Dyne Therapeutics Inc.
Zolmax
10 months ago
Dyne Therapeutics, Inc. (NASDAQ:DYN Get Rating) insider Joshua T. Brumm sold 76,582 shares of Dyne Therapeutics stock in a transaction on Friday, June 9th. The shares were sold at an average price of $13.34, for a total value of $1,021,603.88. Following the completion of the transaction, the insider...
Globe Newswire
1 year ago
- Company Presents Overviews of ACHIEVE and DELIVER Global Clinical Trials with Data Anticipated from Both Studies in the Second Half of 2023 - - FORCEPlatform Achieves Robust Exon Skipping, Restores Dystrophin at the Sarcolemma and Halts Progression of Fibrosis in a Severe In Vivo Model of Duchenne...
Globe Newswire
1 year ago
- Data Anticipated in the Second Half of 2023 from ACHIEVE Clinical Trial of DYNE-101 in DM1 and DELIVER Clinical Trial of DYNE-251 in DMD - WALTHAM, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing ...
Ticker Report
1 year ago
Dyne Therapeutics, Inc. (NASDAQ:DYN Get Rating) insider Jonathan Mcneill sold 10,000 shares of the businesss stock in a transaction that occurred on Wednesday, January 18th. The shares were sold at an average price of $14.03, for a total value of $140,300.00. Following the completion ...
Ticker Report
1 year ago
Dyne Therapeutics, Inc. (NASDAQ:DYN Get Rating) insider Jonathan Mcneill sold 10,000 shares of the businesss stock in a transaction that occurred on Wednesday, January 18th. The shares were sold at an average price of $14.03, for a total value of $140,300.00. Following the completion ...
Frequently Asked Questions
Frequently Asked Questions
What is Dyne Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Dyne Therapeutics Inc shares?
plus_minus_icon
How can I buy Dyne Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Dyne Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Dyne Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Dyne Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Dyne Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Dyne Therapeutics Inc?
plus_minus_icon
What percentage is Dyne Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Dyne Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$27.38
$0.55
(2.05%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00